Page 191 - Drug Class Review
P. 191
Drug Effectiveness Review Project
Drugs Authors: Rösler et al. 57 Country: Europe and North America Novartis Pharma AG, Basle, Switzerland To assess the effects of RIV on the core domains of AD Setting: Multi-center (45 centers in North America and Europe) placebo rivastigmine 6-12 mg/d rivastigmine 1-4 mg/d N/A 6-12 mg/d 1-4 mg/d 26 weeks 26 weeks 26 weeks 239 243 243 50-85 years of age; not able to bear children; met DSM-IV criteria for Alzheimer’s type dementia; met criteria for probable AD according to NINCDS/ADRDA; MMSE scores of 10-26; had a responsible Severe and unstable cardiac disease; sev
Alzheimer Year: 1999 Study design: RCT Sample size: 725 caregiver
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
